Controversy

Whether a universal rCBV threshold for tumor vs treatment effect exists and is transferable across sites

Evidence grade: WEAK — Supported only by weak or preliminary evidence.

computed from the encoded evidence by the Atlas grading rule.

Position A

rCBV is the most reproducible advanced marker; consensus acquisition/postprocessing (leakage correction, normalization) enables standardized thresholds

Position B

Absolute thresholds vary with preload, echo, leakage-correction, and normalization ROI; multi-echo and standardization studies show persistent site dependence

Clinical stakes

Whether rCBV can serve as a decision-grade biomarker rather than a supportive one

Open in the interactive atlas →

About this page

Curated and maintained by Resonant Labs. Reviewed by Claims are synthesized from the cited literature and graded per the Atlas methodology (about the Atlas). Last updated 2026-07-01.

This is an educational research resource from Resonant Labs, not clinical advice. Evidence grades and controversies are summarized from the literature and may change as the field evolves.